Instytut Farmakologii Polskiej Akademii Nauk;Universite de Montpellier;Centre National de la Recherche Scientifique;Uniwersytet Jagiellonski
发明人:
Zajdel, Pawel,Grychowska, Katarzyna,Lamaty, Frederic,Colacino, Evelina,Bantreil, Xavier,Martinez, Jean,Pawlowski, Maciej,Satala, Grzegorz,Bojarski, Andrzej J.,Partyka, Anna,Wesolowska, Anna,Kos, Tomas
申请号：
AU2013394970
公开号：
AU2013394970B2
申请日:
2013.07.25
申请国别(地区):
AU
年份:
2017
代理人:
摘要：
This invention concerns pyrroloquinoline derivatives as antagonists of 5-HT6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in schizophrenia, anxiety, depression, maniac depression, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, panic attacks, attention deficit hyperactivity disorder, attention deficit disorder, Parkinson's disease, Huntington's disease, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, obesity and type-2 diabetes, functional bowel disorder, Irritable Bowel Syndrome. The compounds have the general formula (XIV), wherein the symbols have the meanings given in the description.
